Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Receivables (2020 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Receivables for 6 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 12.37% year-over-year to $2.7 million, compared with a TTM value of $2.7 million through Dec 2025, up 12.37%, and an annual FY2025 reading of $1.3 million, up 616.05% over the prior year.
  • Receivables was $2.7 million for Q4 2025 at Neuroone Medical Technologies, up from $1.3 million in the prior quarter.
  • Across five years, Receivables topped out at $2.7 million in Q4 2025 and bottomed at $24628.0 in Q4 2021.
  • Average Receivables over 5 years is $586182.8, with a median of $213952.0 recorded in 2023.
  • The sharpest move saw Receivables tumbled 65.54% in 2021, then skyrocketed 616.05% in 2025.
  • Year by year, Receivables stood at $24628.0 in 2021, then soared by 287.04% to $95319.0 in 2022, then skyrocketed by 470.08% to $543399.0 in 2023, then surged by 335.94% to $2.4 million in 2024, then grew by 12.37% to $2.7 million in 2025.
  • Business Quant data shows Receivables for NMTC at $2.7 million in Q4 2025, $1.3 million in Q3 2025, and $318780.0 in Q1 2025.